GlassScriptPhysician profile
Jonathan E Wierzbicki
NPI 1104801331
$11,189.16
in general payments reported to CMS, 2019-2025
57 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,222 · 2021: $1,756 · 2022: $1,641 · 2023: $1,680 · 2024: $1,695 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.10 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,410.60 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,591.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,154.43 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $597.81 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.83 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Glaxosmithkline, LLC. | $344.41 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $337.09 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $322.56 | 2019-2025 | |
| Daiichi Sankyo INC. | $238.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $235.56 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.31 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.77 | 2019-2025 | Jardiance, Synjardy |
| Medtronic Minimed, INC. | $208.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.68 | 2019-2025 | Trintellix |
| Antares Pharma, INC. | $187.88 | 2019-2024 | Xyosted, Tlando, Nocdurna |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wierzbicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.